New drug cocktail aims to fight Hard-to-Treat cancers

NCT ID NCT07241936

Recruiting now Disease control Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of sirolimus (a targeted therapy) with several antibody-drug conjugates (ADCs) in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if the combo can shrink tumors. About 444 participants will be enrolled in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus (albumin-bound) combined with antibody-drug conjugates (DP303c, SYS6043, SYS6002, SYS6010)
What this could lead to: If successful, this could point toward a new combination treatment option for advanced solid tumors that are hard to treat.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of patients, so safety and effectiveness are not yet proven. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.